Pharmacokinetics of Antibiotics During Extracorporeal Membrane Oxygenation (ECMO) Support
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 4
- 试验地点
- 1
- 主要终点
- Plasma concentration: cefazolin
研究概览
简要总结
This study will measure plasma concentrations of piperacillin-tazobactam and cefazolin in pediatric patients supported with extracorporeal membrane oxygenation (ECMO) aiming to better understand the pharmacokinetics of these medications in this in vivo setting.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- — 至 18 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •supported on ECMO
- •receive piperacillin-tazobactam or cefazolin as part of routine care or infection management
排除标准
- •>= 18 years
- •No Consent provided
研究组 & 干预措施
Pediatric patients supported on ECMO
干预措施: piperacillin-tazobactam (Drug)
Pediatric patients supported on ECMO
干预措施: Cefazolin (Drug)
结局指标
主要结局
Plasma concentration: cefazolin
时间窗: Peri drug dose administration until cessation of antibiotic therapy or cessation of ECMO support up to a maximum of 4 weeks.
Drug levels will be checked at baseline followed by additional measurements after the dose based on the dosing intervals but anticipated to be 30, 60, 120, 360, 480 minutes after the dose. Dosing regime will be q8-12 hourly pending end organ function (at the discretion of the treating team). The study will be continued for the duration of the Antibiotic therapy whilst on ECMO support and for one set of samples following decannulation.
Plasma concentration: piperacillin-tazobactam
时间窗: Peri drug dose administration until cessation of antibiotic therapy or cessation of ECMO support up to a maximum of 4 weeks.
Drug levels will be checked at baseline followed by additional measurements after the dose based on the dosing intervals but anticipated to be 30, 60, 120, 360, 480 minutes after the dose. Dosing regime will be q8-12 hourly pending end organ function (at the discretion of the treating team). The study will be continued for the duration of the Antibiotic therapy whilst on ECMO support and for one set of samples following decannulation.
次要结局
未报告次要终点
研究者
Katie Moynihan
Cardiac Intensivist
Boston Children's Hospital